DLA Piper advised Triton Pacific Healthcare Partners (Triton Pacific), a healthcare-focused private equity group, and ACON Investments, a global private equity fund, in connection with the sale of BioMatrix Specialty Infusion Pharmacy (BioMatrix) to Frazier Healthcare Partners.
Based in Florida, BioMatrix is one of the largest and most diversified independent providers of specialty infusion services in the US. They deliver a high-touch, patient-centric model built around therapeutic centers of excellence that provide superior management of patient therapies, including IVIG, bleeding disorders, immunology, neurology, transplant, oncology, and rare diseases.
Founded in 2001, Triton Pacific is a private equity firm offering investment opportunities to institutional and high net worth investors. Its healthcare division, Triton Pacific Healthcare Partners, has a dedicated healthcare investment team with a demonstrated track record of successfully sourcing, acquiring, and managing healthcare investments.
“We are witnessing substantial headwinds in support of infusion services. We look forward to continue working with clients investing in this emerging industry,” said Joshua Kaye, chair of DLA Piper’s US Healthcare sector who led the deal team.
In addition to Kaye (Miami), the DLA Piper team included partners Sal Favuzza (Miami), Rachel Ludwig (Washington, DC), and Jordan Bailowitz (Baltimore), and associates Hunter Boyett (Miami) and Mike Fehser (Phoenix).
With more than 225 global lawyers who provide strategic counsel to private equity funds and their industry-leading portfolio companies, DLA Piper’s Private Equity practice has the capacity, experience and relationships to help drive value across the investment life cycle by delivering responsive, efficient and integrated solutions around the world.
DLA Piper’s globally recognized life sciences team has spent decades helping entrepreneurs, companies, innovators, and investors turn their most promising and disruptive ideas into successful businesses. Drawing on diverse backgrounds in the legal, financial, and medical sectors and beyond, our team brings a distinctive blend of experience to develop client-focused solutions. We understand the unique challenges life science companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new paths to profitability, and protecting existing innovation. Our approach delivers both strategic and practical counsel to clients, ultimately leading to better human outcomes.